Kygevvi: which tox species, and why?

“The nonclinical safety program supporting the clinical development and approval of doxecitine and doxribtimine included repeat-dose oral toxicity studies in mice (up to 4 weeks), rats (up to 6 months), and dogs (up to 3 months)”

“The studies, conducted in alignment with ICH guidelines, utilized mouse, rat, rabbit, and dog models, leveraging shared mitochondrial TK2 nucleoside phosphorylation and cytosolic nucleoside pathways, as well as conserved mitochondrial genomes and incorporation pathways analogous to those in humans.”

“In dogs, doxecitine and doxribtimine up to 100 mg/kg/day (doxecitine 50 mg/kg/day and doxribtimine 50 mg/kg/day) for 13 weeks.”